(0.58%) 5 075.75 points
(0.34%) 38 198 points
(0.79%) 17 576 points
(0.71%) $79.56
(2.28%) $1.976
(0.21%) $2 315.80
(-0.24%) $26.69
(0.93%) $963.80
(0.11%) $0.934
(0.33%) $11.07
(0.03%) $0.799
(0.37%) $93.60
3.57% HKD 1.740
Live Chart Being Loaded With Signals
TOT BIOPHARM International Company Limited, an investment holding company, engages in the research and development, manufacture, and marketing of anti-tumor drugs in the People's Republic of China...
Stats | |
---|---|
Dzisiejszy wolumen | 84 400.00 |
Średni wolumen | 40 310.00 |
Kapitalizacja rynkowa | 1.26B |
EPS | HKD0 ( 2024-03-22 ) |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -34.80 |
ATR14 | HKD0 (0.00%) |
TOT BIOPHARM Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
TOT BIOPHARM Finanse
Annual | 2023 |
Przychody: | HKD780.63M |
Zysk brutto: | HKD573.99M (73.53 %) |
EPS: | HKD-0.0521 |
FY | 2023 |
Przychody: | HKD780.63M |
Zysk brutto: | HKD573.99M (73.53 %) |
EPS: | HKD-0.0521 |
FY | 2022 |
Przychody: | HKD442.18M |
Zysk brutto: | HKD370.62M (83.82 %) |
EPS: | HKD-0.0781 |
FY | 2021 |
Przychody: | HKD76.33M |
Zysk brutto: | HKD27.47M (36.00 %) |
EPS: | HKD-0.458 |
Financial Reports:
No articles found.
TOT BIOPHARM
TOT BIOPHARM International Company Limited, an investment holding company, engages in the research and development, manufacture, and marketing of anti-tumor drugs in the People's Republic of China. The company's principal drug candidate is TAB008 for the treatment of non-squamous non-small-cell lung cancer metastatic colorectal cancer, glioblastoma multiforme, ovarian cancer, cervical cancer, and hepatocellular carcinoma. It also offers TOZ309 for malignant brain tumor. Further, the company develops TAA013 for HER2+ breast cancer which is under Phase III clinical trial; TAE020 which is under preclinical trial for acute myeloid leukemia; TAB014 for wet age-related macular degeneration and is under Phase II clinical trial. In addition, it develops TAY018 for non-Hodgkin's lymphoma, myelodysplastic syndrome, acute myelogenous leukemia, and solid tumors; TAC020 for various solid tumors; TEP118 for biliary cancer, gallbladder tumors, metastatic cancer, non-small-cell lung cancer (NSCLC), and gastric cancer; TOM312 for cancer and HIV-associated cachexia; TIC318 for epithelial-derived ovarian cancer, small-cell lung cancer, head and neck squamous cell carcinoma, testicular tumors, malignant lymphoma, cervical cancer, bladder cancer, and NSCLC; TVP211 and TID214 for solid tumors; and TIO217 for gastrointestinal tumors. TOT BIOPHARM International Company Limited was incorporated in 2009 and is headquartered in Suzhou, the People's Republic of China.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej